AF9 抗体 (C-Term)
Quick Overview for AF9 抗体 (C-Term) (ABIN390128)
抗原
See all AF9 (MLLT3) 抗体适用
宿主
克隆类型
标记
应用范围
克隆位点
-
-
抗原表位
- AA 471-502, C-Term
-
预测反应
- M
-
纯化方法
- This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
-
免疫原
- This AF9 (MLLT3) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 471-502 amino acids from the C-terminal region of human AF9 (MLLT3).
-
亚型
- Ig Fraction
-
-
-
-
应用备注
- WB: 1:1000. IHC-P: 1:50~100
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
缓冲液
- Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
-
储存液
- Sodium azide
-
注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
储存条件
- 4 °C,-20 °C
-
储存方法
- Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.
-
有效期
- 6 months
-
-
-
: "The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures." in: Leukemia, Vol. 25, Issue 1, pp. 135-44, (2011) (PubMed).
: "The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling." in: Human molecular genetics, Vol. 16, Issue 1, pp. 92-106, (2007) (PubMed).
-
: "The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures." in: Leukemia, Vol. 25, Issue 1, pp. 135-44, (2011) (PubMed).
-
- AF9 (MLLT3) (Protein AF-9 (MLLT3))
-
别名
- AF9 (MLLT3)
-
背景
- The human AF9 gene is one of the most common fusion partner genes with the ALL1 gene at 11q23 (also called MLL), resulting in the t(9,11)(p22,q23). The AF9 gene is more than 100 kb, and 2 patient breakpoint cluster regions (BCRs) have been identified, BCR1 is within intron 4, previously called site A, whereas BCR2 or site B spans introns 7 and 8. Several different structural elements have been identified in AF9, including a colocalizing in vivo DNA topo II cleavage site and an in vitro DNase I hypersensitive (DNase 1 HS) site in intron 7 in BCR2. Reversibility experiments demonstrated a religation of the topo II cleavage sites. In addition, 2 scaffold associated regions (SARs) are located centromeric to the topo II and DNase I HS cleavage sites and border breakpoint regions in 2 leukemic cells lines: SAR1 is located in intron 4, whereas SAR2 encompasses parts of exons 5-7. The patient breakpoint regions of AF9 share the same structural elements as the MLL BCR. A DNA breakage and repair model for nonhomologous recombination between MLL and its partner genes, particularly AF9, has been proposed.
-
分子量
- 63351
-
基因ID
- 4300
-
NCBI登录号
- NP_004520
-
UniProt
- P42568
抗原
-